Hydrocortisone for prevention or treatment of bronchopulmonary dysplasia: long-term neurodevelopmental safety and efficacy—a meta-analysis of randomized clinical trials - Top-Institutions - MDSpire

Hydrocortisone for prevention or treatment of bronchopulmonary dysplasia: long-term neurodevelopmental safety and efficacy—a meta-analysis of randomized clinical trials

  • By

  • Kawthar Ahmed Shehab

  • Rahaf Muslih N. Almatrafi

  • Ethar Ali

  • Yara Albargi

  • Sama Saabi

  • Halah Alhassan Aljohani

  • Rayan Nabil Almuhanna

  • Raghad Alnaami

  • Khalid Abdulrahman Almehery

  • Reema Safar Alamri

  • Sarah Ahmed A. Baqer

  • Shouq Naif Aloufi

  • Ahmed Elaraby

  • Bedah Mohammed Alnawfal

  • June 24, 2026

  • 0 min

Share

Top Institutions in Pediatrics

Brief introduction explaining scope and methodology.

  • #1

    Children’s Hospital of Philadelphia
    Children’s Hospital of Philadelphia

    Philadelphia, Pennsylvania

    Key Differentiators

    • Pediatrics
    • Neonatology

  • #2

    Stanford University – Lucile Packard Children’s Hospital Stanford
    Stanford University – Lucile Packard Children’s Hospital Stanford

    Palo Alto, California

    Key Differentiators

    • Pediatrics
    • Neonatology

Original Source(s)

Hydrocortisone for prevention or treatment of bronchopulmonary dysplasia: long-term neurodevelopmental safety and efficacy—a meta-analysis of randomized clinical trials

  • by Kawthar Ahmed Shehab, Rahaf Muslih N. Almatrafi, Ethar Ali, Yara Albargi, Sama Saabi, Halah Alhassan Aljohani, Rayan Nabil Almuhanna, Raghad Alnaami, Khalid Abdulrahman Almehery, Reema Safar Alamri, Sarah Ahmed A. Baqer, Shouq Naif Aloufi, Ahmed Elaraby, Bedah Mohammed Alnawfal

  • June 24, 2026

Related Content

Case Report: Primary hemophagocytic lymphohistiocytosis with a homozygous PRF1 variant: a case suggesting early immunoporosis and an expanded phenotypic spectrum

Virtual Care Remuneration Policy and Postdischarge Follow-Up Trends

The therapeutic potential of natural products for pediatric psoriasis: targeting the immune microenvironment